Skip to content
AnalystLens

BridgeBio Pharma 8-K Report, Financial Results (May 7, 2026)

Reports
Earnings & Results·Other Events
Filing Date
Filed May 7, 2026
Period End
May 6, 2026
Security
BBIO
In the record · 2019–202610-K710-Q238-K107

BBIO filed 7 annual reports (10-K), 23 quarterly reports (10-Q) and 107 current reports (8-K) between 2019 and 2026.

  1. Leadership change8-K · Feb ’20Feb ’20
  2. Leadership change8-K · Oct ’21Oct ’21
  3. Material agreement8-K · Sep ’23Sep ’23
  4. Material agreement8-K · Jul ’25Jul ’25

Summary

Summary of the 8-K filed May 7, 2026. Cited figures are marked; the original filing is the authoritative source.

BridgeBio Pharma, Inc. (Nasdaq: BBIO) reported first-quarter 2026 results on May 7, 2026, with total revenues, net of $194.5 milliona, up from $116.6 million a year earlier.

The increase was driven mainly by a $143.9 millionb rise in net product revenue from Attruby, to $180.6 million, and a $9.3 million rise in royalty revenue. Total operating costs and expenses rose to $300.5 million from $221.0 million, led by higher SG&A spending tied to Attruby commercialization and pre-commercial activities for its Phase 3 candidates. The net loss attributable to common stockholders of BridgeBio was $164.0 million, or $0.84 per share, compared with $167.4 million, or $0.88 per share, in the prior-year quarter.

Cash, cash equivalents and marketable securities were $940.2 millionc at March 31, 2026, up from $587.5 million at December 31, 2025. The Board approved a share repurchase program of up to $500 million of common stock on May 6, 2026. The filing states that repurchases may be made in the open market or in privately negotiated transactions, and that the program does not obligate the company to repurchase any amount and may be suspended or discontinued at any time.

The CEO's quoted remarks say the company is fully financed and trading at a deep discount to intrinsic value, which is why it considers buybacks prudent. Pipeline news includes the first of three planned NDAs submitted to the FDA for BBP-418 in LGMD2I/R9, with encaleret for ADH1 NDA submission planned for the first half of 2026 and oral infigratinib for achondroplasia planned for the third quarter of 2026. The filing also reports Brazilian approval of acoramidis (BEYONTTRA) for ATTR-CM on May 4, 2026.

Key Highlights

  1. Total revenues, net of $194.5 million for Q1 2026, versus $116.6 million in Q1 2025, including $180.6 million of U.S. Attruby net product revenue.
  2. Total operating costs and expenses rose to $300.5 million from $221.0 million, with SG&A up $57.5 million to support Attruby commercialization and pre-commercial launch activities.
  3. Net loss attributable to common stockholders of BridgeBio was $164.0 million, or $0.84 per share, compared with $167.4 million, or $0.88 per share, a year earlier.
  4. Cash, cash equivalents and marketable securities increased to $940.2 million at March 31, 2026, from $587.5 million at December 31, 2025.
  5. Board authorized a share repurchase program of up to $500 million of common stock on May 6, 2026, with no obligation to repurchase and the right to suspend or discontinue at any time.
  6. BBP-418 NDA submitted to the FDA for LGMD2I/R9, the first of three planned NDAs; encaleret NDA for ADH1 is planned for 1H 2026 and infigratinib NDA for achondroplasia for Q3 2026.
  7. Attruby demonstrated a statistically significant 44.7% reduction in all-cause mortality and 49.3% reduction in cardiovascular mortality through Month 54 in an open-label extension study, with Brazil approval of BEYONTTRA (acoramidis) on May 4, 2026.

Frequently Asked Questions

  1. What drove the increase in BridgeBio's first-quarter 2026 revenue?

    Total revenues, net rose $77.9 million to $194.5 million, primarily because net product revenue from Attruby increased $143.9 million and royalty revenue increased $9.3 million, mainly from BEYONTTRA net product sales in the EU and Japan. License and services revenue declined because the prior-year period included $75.0 million of milestone-related revenue.

  2. Why did operating expenses increase, and what is the company spending on?

    Total operating costs and expenses increased $79.5 million to $300.5 million. The filing attributes this mainly to a $57.5 million rise in SG&A, reflecting continued Attruby commercialization and pre-commercial activities for Phase 3 product candidates, a $15.2 million increase in R&D to support late-stage programs, and a $7.3 million increase in total cost of revenues, primarily product costs of Attruby.

  3. What is the new $500 million share repurchase program, and how will it be executed?

    The Board approved on May 6, 2026 a program to buy up to $500 million of outstanding common stock. Purchases may be made from time to time in the open market, in privately negotiated transactions or otherwise, in accordance with applicable securities laws including Rule 10b-18. Timing, pricing and amounts depend on market price and general market conditions. The program does not obligate the company to repurchase any amount and may be suspended or discontinued at any time.

  4. How much cash does BridgeBio have, and how did its balance change?

    Cash, cash equivalents and marketable securities totaled $940.2 million at March 31, 2026, up from $587.5 million at December 31, 2025. The company's cash flow statement shows $562.5 million in Q1 2026 proceeds from notes issuance, $632.5 million gross of 2033 Notes before $12.8 million of issuance costs and discounts, offset by $197.3 million of net cash used in operating activities and $82.5 million of common stock repurchases.

  5. What are the key upcoming regulatory and clinical milestones?

    The company has submitted an NDA for BBP-418 in LGMD2I/R9, which may be eligible for priority review, and expects a U.S. launch in late 2026 or early 2027. It plans to submit an NDA for encaleret in ADH1 in the first half of 2026 and an NDA for oral infigratinib in achondroplasia in Q3 2026. Additional Attruby data will be presented at Heart Failure 2026 on May 11, 2026, and CALIBRATE results at the 2026 European Congress of Endocrinology on May 12, 2026.